X-Waiver No Longer Required to Treat Opioid Use Disorder
In DEA guidance released in Jan 2023, an X-Waiver is no longer required to treat patients with buprenorphine for opioid use disorder. ACEP has more details about treatment options and training requir...
EM Opioid Advisory Network
COMPASS Huntington: A Unique First Responder Wellness Center
Fentanyl and Induction in the age of Fentanyl
Resources
Buprenorphine after Naloxone
Passing the Time After Opioid Stuffing in Asymptomatic Adults
6 Part Webinar Series on Opioid Use Disorder, Federal and State Regulations, Regulatory Considerations, and State Initiatives
Opioids
ACEP Hosts Summit on Impact of Stigma and OUD in Emergency Settings
Join Our Interest List
Accreditation Levels
Frequently Asked Questions
Pain and Addiction Care in the ED
Sex-Based Differences in Opioid-Induced Respiratory Depression
Bills in the House & Senate to “Deregulate” Buprenorphine and Other Legislative & Regulatory News
PDMP Legislation
Naloxone Legislation
Pain Management
Continuing Medical Education
State Specific Policies
Myths and Facts of Opioid Policy Advocacy
Opioid Prescribing Legislation
Opioid Advocacy Resources
You’ve Got a Friend: Eva’s Village Opioid Overdose Recovery Program and Peer Recovery Specialists
